Actinium Pharmaceuticals To Present Data And Preclinical Results For ANTM-400 At The Congress Of The European Association Of Nuclear Medicine, October 17–21

Actinium Pharmaceuticals will present data and preclinical results for its drug ATNM-400 at the Congress of the European Association of Nuclear Medicine from October 17-21, 2026. The Phase 1 study will focus on metastatic castration-resistant prostate cancer, while preclinical studies will explore its application in KRAS- and ALK-driven non-small cell lung cancer. ATNM-400 employs a HER3-targeted alpha radiotherapy approach, indicating potential use as both a monotherapy and in combination with existing treatments across various solid tumors.